Latest Breaking News On - Fellowship at sierra eye associates - Page 1 : vimarsana.com

Opthea : Quarterly Activity Report - Form 6-K

Quarterly Activity Report Q3 FY24 Highlights • Completion of enrolment in first trial of sozinibercept s Phase 3 pivotal program.

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

Global retina expert joins to support sozinibercept development and launch preparationMELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani i

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor - Opthea (NASDAQ:OPT)

MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive

Vial to Sponsor and Present at Clinical Trials at the Summit (CTS) 2023 in Park City, UT

/PRNewswire/ Vial, a global tech-first CRO providing next-generation clinical trial management services, announced it will be sponsoring and presenting at.

Clearside Biomedical (CLSD) Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX in Wet AMD Patients